191 related articles for article (PubMed ID: 24516352)
1. Comparison of the inhibitory effect of gonadotropin releasing hormone (GnRH) agonist, selective estrogen receptor modulator (SERM), antiprogesterone on myoma cell proliferation in vitro.
Chung YJ; Chae B; Kwak SH; Song JY; Lee AW; Jo HH; Lew YO; Kim JH; Kim MR
Int J Med Sci; 2014; 11(3):276-81. PubMed ID: 24516352
[TBL] [Abstract][Full Text] [Related]
2. Changes in proliferating and apoptotic markers of leiomyoma following treatment with a selective progesterone receptor modulator or gonadotropin-releasing hormone agonist.
Yun BS; Seong SJ; Cha DH; Kim JY; Kim ML; Shim JY; Park JE
Eur J Obstet Gynecol Reprod Biol; 2015 Aug; 191():62-7. PubMed ID: 26093349
[TBL] [Abstract][Full Text] [Related]
3. Ultrastructural comparison of uterine leiomyoma cells from the same myoma nodule before and after gonadotropin-releasing hormone agonist treatment.
Ito F; Kawamura N; Ichimura T; Tsujimura A; Ishiko O; Ogita S
Fertil Steril; 2001 Jan; 75(1):125-30. PubMed ID: 11163826
[TBL] [Abstract][Full Text] [Related]
4. Oestrogen deficiency causes DNA damage in uterine leiomyoma cells: a possible mechanism for shrinkage of fibroids by GnRH agonists.
Cheng YM; Chou CY; Huang SC; Lin HC
BJOG; 2001 Jan; 108(1):95-102. PubMed ID: 11213012
[TBL] [Abstract][Full Text] [Related]
5. Long-term effectiveness and safety of GnRH agonist plus raloxifene administration in women with uterine leiomyomas.
Palomba S; Orio F; Russo T; Falbo A; Cascella T; Doldo P; Nappi C; Lombardi G; Mastrantonio P; Zullo F
Hum Reprod; 2004 Jun; 19(6):1308-14. PubMed ID: 15117890
[TBL] [Abstract][Full Text] [Related]
6. Cellular proliferation, estrogen receptor, progesterone receptor, and bcl-2 expression in GnRH agonist-treated uterine leiomyomas.
Vu K; Greenspan DL; Wu TC; Zacur HA; Kurman RJ
Hum Pathol; 1998 Apr; 29(4):359-63. PubMed ID: 9563785
[TBL] [Abstract][Full Text] [Related]
7. Beneficial effects of dienogest on uterine myoma volume: a retrospective controlled study comparing with gonadotropin-releasing hormone agonist.
Ichigo S; Takagi H; Matsunami K; Suzuki N; Imai A
Arch Gynecol Obstet; 2011 Sep; 284(3):667-70. PubMed ID: 21052701
[TBL] [Abstract][Full Text] [Related]
8. A randomized, controlled clinical trial comparing the effects of aromatase inhibitor (letrozole) and gonadotropin-releasing hormone agonist (triptorelin) on uterine leiomyoma volume and hormonal status.
Parsanezhad ME; Azmoon M; Alborzi S; Rajaeefard A; Zarei A; Kazerooni T; Frank V; Schmidt EH
Fertil Steril; 2010 Jan; 93(1):192-8. PubMed ID: 19135657
[TBL] [Abstract][Full Text] [Related]
9. Selective estrogen receptor modulator and selective progesterone receptor modulator: therapeutic efficacy in the treatment of uterine leiomyoma.
Ohara N
Clin Exp Obstet Gynecol; 2005; 32(1):9-11. PubMed ID: 15864926
[TBL] [Abstract][Full Text] [Related]
10. Association of the shrinkage of uterine leiomyoma treated with GnRH agonist and deletion of long arm of chromosome 7.
Takahashi K; Kawamura N; Tsujimura A; Ichimura T; Ito F; Ishiko O; Ogita S
Int J Oncol; 2001 Jun; 18(6):1259-63. PubMed ID: 11351260
[TBL] [Abstract][Full Text] [Related]
11. Studies on leptin and leptin receptor gene expression in myometrium and uterine myomas of gnRH analogue-treated women.
Markowska A; Rucinski M; Drews K; Malendowicz LK
Eur J Gynaecol Oncol; 2006; 27(4):379-84. PubMed ID: 17009630
[TBL] [Abstract][Full Text] [Related]
12. Use of a gonadotropin-releasing hormone agonist to manage perimenopausal women with symptomatic uterine myomas.
Wang PH; Lee WL; Cheng MH; Yen MS; Chao KC; Chao HT
Taiwan J Obstet Gynecol; 2009 Jun; 48(2):133-7. PubMed ID: 19574174
[TBL] [Abstract][Full Text] [Related]
13. Shrinkage effect of gonadotropin releasing hormone agonist treatment on uterine leiomyomas and t(12;14).
Takahashi K; Kawamura N; Ishiko O; Ogita S
Int J Oncol; 2002 Feb; 20(2):279-83. PubMed ID: 11788889
[TBL] [Abstract][Full Text] [Related]
14. Down-regulation of proliferation and up-regulation of apoptosis by gonadotropin-releasing hormone agonist in cultured uterine leiomyoma cells.
Wang Y; Matsuo H; Kurachi O; Maruo T
Eur J Endocrinol; 2002 Mar; 146(3):447-56. PubMed ID: 11888853
[TBL] [Abstract][Full Text] [Related]
15. Gonadotropin-releasing hormone (GnRH) agonist leuprolide acetate and GnRH antagonist cetrorelix acetate directly inhibit leiomyoma extracellular matrix production.
Britten JL; Malik M; Levy G; Mendoza M; Catherino WH
Fertil Steril; 2012 Nov; 98(5):1299-307. PubMed ID: 22901846
[TBL] [Abstract][Full Text] [Related]
16. Cell proliferation effect of GnRH agonist on pathological lesions of women with endometriosis, adenomyosis and uterine myoma.
Khan KN; Kitajima M; Hiraki K; Fujishita A; Nakashima M; Ishimaru T; Masuzaki H
Hum Reprod; 2010 Nov; 25(11):2878-90. PubMed ID: 20829343
[TBL] [Abstract][Full Text] [Related]
17. Gonadotropin-releasing hormone agonist increases expression of osmotic response genes in leiomyoma cells.
McCarthy-Keith DM; Malik M; Britten J; Segars J; Catherino WH
Fertil Steril; 2011 Jun; 95(7):2383-7. PubMed ID: 21496801
[TBL] [Abstract][Full Text] [Related]
18. Guideline No. 389-Medical Management of Symptomatic Uterine Leiomyomas - An Addendum.
Laberge PY; Murji A; Vilos GA; Allaire C; Leyland N; Singh SS
J Obstet Gynaecol Can; 2019 Oct; 41(10):1521-1524. PubMed ID: 31548041
[TBL] [Abstract][Full Text] [Related]
19. Vaginal expulsion of a submucosal myoma during treatment with long-acting gonadotropin-releasing hormone agonist.
Wen L; Tseng JY; Wang PH
Taiwan J Obstet Gynecol; 2006 Jun; 45(2):173-5. PubMed ID: 17197363
[TBL] [Abstract][Full Text] [Related]
20. Enhanced deoxyribonucleic acid damage and repair but unchanged apoptosis in uterine leiomyomas treated with gonadotropin-releasing hormone agonist.
Huang SC; Chou CY; Lin YS; Tsai YC; Hsu KF; Liu CH; Huang KE
Am J Obstet Gynecol; 1997 Aug; 177(2):417-24. PubMed ID: 9290461
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
